RESEARCH



Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial

Christian Maurer^{1,2} · Elisa Agostinetto³ · Lieveke Ameye³ · Matteo Lambertini^{4,5} · Samuel Martel^{6,7} · Noam Ponde⁸ · Mariana Brandão³ · Francesca Poggio⁵ · Arlindo Ferreira⁹ · Rachel Schiff¹⁰ · Carmine De Angelis¹¹ · Richard D. Gelber¹² · Susan Dent¹³ · Christoph Thomssen¹⁴ · Martine Piccart³ · Evandro de Azambuja³

Received: 11 February 2025 / Accepted: 4 April 2025 / Published online: 28 April 2025 © The Author(s) 2025

Abstract

Purpose There is evidence that statins might improve the outcome of patients with breast cancer. The role of statins in patients with early HER2-positive breast cancer is unknown. Therefore, we explored the association between statin use and survival outcomes in early HER2-positive breast cancer patients in the phase III APHINITY trial (adjuvant pertuzumab/ trastuzumab).

Methods All patients (intent-to-treat population, n = 4804) were included (6.2 years median follow-up database). The primary objective was to investigate the association of statin use on invasive disease-free survival (IDFS), distant relapse-free interval (DRFI), and overall survival (OS). Patients who received statins at baseline, or started statins within 1 year from randomization were considered statin users. Survival curves were estimated using the Kaplan–Meier method. We used a Cox proportional hazards model for multivariate analysis.

Results Overall, 423 (8.8%) patients were classified as statin users. They were older, more often postmenopausal, had a higher body mass index, more often diabetes, hypertension, coronary heart disease and hyperlipidemia, had smaller sized tumors, were treated more often with breast conserving surgery, and less often with anthracycline-containing regimens. Overall, 508 IDFS events (12.8% among statin users and 10.4% among non-statin users) and 272 deaths (8.5% and 5.4%, respectively) occurred. In multivariate analysis, statin use was not associated with IDFS (HR, 1.11; 95% CI, 0.80–1.52), DRFI (HR, 1.21; 95% CI, 0.81–1.81) nor OS (HR, 1.16; 95% CI, 0.78–1.73).

Conclusion In APHINITY, statin use was not associated with improved survival outcomes. These results must be interpreted with caution due to the exploratory nature of the analysis and the associated limitations.

Keywords Breast cancer · HER2-positive · Statins · Pertuzumab · Trastuzumab

Introduction

About 15%–20% of all breast cancers (BC) show overexpression/amplification of the human epidermal growth factor receptor 2 (HER2). In the absence of specific anti-HER2 treatments, HER2-positive (HER2+) BC is an aggressive BC subtype with worse prognosis than hormone receptorpositive disease. Targeting the HER2 pathway has led to marked improvement in the outcome of patients in both early and advanced disease settings [1, 2]. However, despite the efficacy of anti-HER2 drugs and the improved outcomes seen with combination of different HER2-pathway inhibitors, resistance remains a clinical challenge [3]. Comorbidities are present in 32–42% of BC patients, with hypertension being most common, followed by other cardiovascular diseases and type 2 diabetes [4]. Accordingly, many patients with BC are prescribed medications, including statins, for such conditions. In addition to cholesterol biosynthesis, the mevalonate pathway, via isoprenoid intermediates, can generate cell proliferative and survival signals [5]. Preclinical evidence suggested that the mevalonate pathway might play a role in tumor initiation and progression [6]. The rate-limiting enzyme of the mevalonate pathway is the hydroxymethylglutaryl coenzyme A reductase, which can be inhibited by statins. Preclinical work, including BC models, suggested that statins might induce apoptosis and reduce tumor growth, angiogenesis, and metastases [7, 8]. Observational studies have

Extended author information available on the last page of the article

provided conflicting data regarding the possible impact of statins on breast cancer outcomes. The definition of statin users differed between the studies which makes comparability difficult. Some observational studies, including two meta-analyses, suggested a protective association between statin use and breast-cancer specific death and/or overall survival (OS) [9–22], while other studies have not shown a positive effect of statins on this survival outcome [23–31]. Regarding BC recurrence, some studies have reported that statin use correlates with better outcomes [16–18, 21, 25, 29, 32–35], while others have not found this association [20, 27, 28, 30, 36–39].

Preclinical models suggested that the mevalonate pathway acts as an escape mechanism of survival and growth in HER2 + BC resistant to anti-HER2 therapies. Inhibitors of the pathway with simvastatin resulted in apoptosis and growth inhibition of resistant BC cells [40]. Examining the association between statin use and the outcome of patients with HER2 + BC is therefore warranted. Accordingly, we investigated the association between statin use and survival outcomes in patients with early HER2 + BC enrolled in the APHINITY trial.

Methods

APHINITY is a prospective, randomized, double-blind phase 3 trial that tested the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2 + BC. Overall, 4805 patients were randomly assigned to receive chemotherapy and trastuzumab plus either pertuzumab or placebo. The addition of pertuzumab was associated with an improved invasive disease-free survival (IDFS). Yet this benefit was restricted to patients with node-positive disease. Detailed information regarding study design, eligibility, conduct and results were previously reported [41–43].

Study population

All patients in the intent-to-treat population (n = 4804) were included in the current analysis, at a median follow-up of 6.2 years. Trial baseline case report forms collected comedications and investigators were asked to document any new treatment, irrespective of its duration, throughout the conduct of the trial. Patients who received statins at baseline, or started statins within 1 year from randomization were considered statin users. To prevent lead-time-bias, patients with start of statins more than 1 year from randomization were considered non-users.

Primary outcome

The primary objective of this sub-study was to determine the association between statin use and outcomes in terms of IDFS, distant relapse-free interval (DRFI), and OS. For IDFS, DRFI and OS the same definitions as in the APHIN-ITY trial were used [41]. IDFS is defined as the time from randomization until the date of the first occurrence of ipsilateral invasive breast tumor, recurrence of ipsilateral locoregional invasive disease, a distant disease recurrence, contralateral invasive BC, or death from any cause. DRFI is defined as the time between randomization and the date of distant BC recurrence. OS is defined as the time from randomization to death due to any cause.

Statistical analysis

Patients' and tumor baseline characteristics were compared with respect to the presence or absence of statin co-medication using the chi-square test. Survival curves for IDFS, DRFI, and OS according to the presence or absence of statin co-medication were estimated using the Kaplan Meier method. In univariate analysis, the association of statin use (statin use, lipophilic and hydrophilic statins = 3 groups) was assessed, stratified by randomized arm (pertuzumab versus [vs] placebo), menopausal status (premenopausal vs postmenopausal), hormone receptor status (negative vs positive; centrally assessed) and body mass index (BMI; normal [20-24.9 kg/m²] vs overweight $[25.0-29.9 \text{ kg/m}^2]$ vs obese $[\geq 30.0 \text{ kg/m}^2]$). Considering multiple testing with respective type I error increase, a Bonferroni testing was applied and a *p*-value < 0.00167 (i.e., 0.05/30 [10 groups $\times 3$ tests]) was considered statistically significant. A multivariate analysis using a Cox proportional hazard model was used to assess the association of statin use adjusted for age (< 65 vs \geq 65 years), menopausal status (premenopausal vs postmenopausal), BMI (< 30 kg/m² vs 30–34.9 kg/m² vs \ge 35 kg/m²), tumor size (< 2 cm vs \ge 2 < 5 cm vs \ge 5 cm), nodal status (none vs 1–3 vs \geq 4 positive lymph nodes), hormone receptor status (negative vs positive), existence of comorbidities (diabetes, hypertension and coronary heart disease; as noted by the investigators), and treatment arm (placebo vs pertuzumab). A fixed time Cox model with starting timepoint of randomization was used as primary analysis. Interaction terms were considered between statin use at any time and treatment arm, hormone receptor status and BMI. A multivariate competing risk analysis for OS was performed considering cause of death other than breast cancer as a competing risk. Two sensitivity analyses for the association of statin use with IDFS, DRFI and OS were performed (Cox model adjusting for the same variables as above): 1) considering a landmark at 12 months (i.e., start at 1 year after randomization), and 2) considering start of statin use as a time-dependent variable. Statistical analysis was conducted using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).

Results

Patient population

Of the 4804 patients of the intent-to-treat population, 423 patients (8.8%) were classified as statin users (n = 302 only lipophilic statin users, n = 116 only hydrophilic statin users and n = 5 lipophilic and hydrophilic statin users). For the majority of statin users (n = 230, 54.4%), exact start and stop dates of statin treatment were missing. For 42 statin users (9.9%), start and stop dates of statin treatment were available. For these patients, median time on statins was 5 months (interquartile range [IQR], 2-34 months). For the rest of the statin users, either start date (n = 32; 7.6%) or end date (n = 119; 28.1%) was missing. The majority of statin users (91.5%) were on statin treatment at baseline and during study treatment. Twenty-five patients (5.9%) started statin treatment after randomization (median time from randomization to treatment start, 2.3 months; IQR, 2 days-6.6 months). Two patients started statin treatment more than 1 year after randomization and were considered non-statin users. Table 1 illustrates the baseline characteristics of the study population. Compared to non-statin users, statin users were older (median age, 62 vs 50 years), more frequently postmenopausal (91.1% vs 47.6%), had a higher BMI (median, 27.3 kg/m²) vs 24.4 kg/m²), had smaller sized tumors (≤ 1.9 cm, 46.1% vs 39.5%), were treated more often with breast conserving surgery than with mastectomy (54.1% vs 44.9%), were treated less frequently with anthracycline-containing regimens (71.4% vs 78.6%) and were more often diagnosed with diabetes (24.6% vs 3.9%), hypertension (64.1% vs 18.4%), coronary heart disease (4.0% vs 0.6%) and hyperlipidemia (83.0% vs 3.4%).

Survival outcomes

The median follow-up for OS was 73.8 months (IQR, 69.3–75.5 months) for statin users and 74.1 months (IQR, 69.3–75.5 months) for non-statin users. Overall, 508 IDFS events (54/423 [12.8%] among statin users and 454/4381 [10.4%] among non-statin users), 343 DRFI events (33/423 [7.8%] and 310/4381 [7.1%], respectively) and 272 deaths (36/423 [8.5%] and 236/4381 [5.4%], respectively) occurred. The most common cause of death was related to recurrence of BC (n = 187; 69%). Of the 36 deaths among statin users,

21 [58.3%] were due to recurrence of disease. Of the 236 deaths among the non-statin users, 166 [70.3%] were due to recurrence of disease. Numerically, there were more non-BC-related deaths in statin users (n = 15; 41.7%) than in non-statin users (n = 70; 29.7%). Figure 1 shows the Kaplan Meier curves for IDFS, DRFI, and OS. Applying the Bonferroni correction with a *p*-value <0.00167 for statistical significance, statin use had no association with IDFS (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.95–1.68; *p*-value = 0.10) or DRFI (HR, 1.13; 95% CI, 0.79–1.61; *p*-value = 0.52) in univariate analysis. Regarding OS, statin use overall was associated with a trend to worse outcome in univariate analysis (HR, 1.62, 95% CI, 1.14–2.31; *p*-value 0.007) without reaching statistical significance.

Supplementary Table 1 (Supplementary Information) shows the univariate analysis of IDFS, DRFI and OS stratified by treatment arm, menopausal status, hormone receptor status and BMI. No subgroup was identified that showed a significant association between statin use and IDFS, DRFI nor OS: When stratified by treatment arm within the APHINITY trial, menopausal status, BMI, tumor size, nodal status or hormone receptor status, treatment with statins in general, lipohilic or hydrophilic statins was not associated with survival outcomes. In multivariate analysis, no association was observed between statin use and IDFS (HR, 1.11; 95% CI, 0.80–1.52; *p*- value = 0.54), DRFI (HR, 1.21; 95% CI, 0.81–1.81; *p*-value = 0.35) or OS (HR, 1.16; 95% CI, 0.78–1.73; *p*-value = 0.45) (Table 2). These findings were confirmed in the two sensitivity analyses (Table 3).

Discussion

In this exploratory analysis of the APHINITY trial, we investigated the association of statin treatment and clinical outcomes of patients with early HER2 + BC treated with chemotherapy plus trastuzumab with or without pertuzumab. Previous studies provide clinical evidence suggesting a protective role of statins in patients with BC. In the BIG 1-98 trial, use of cholesterol-lowering medications was associated with improved outcome among 8010 postmenopausal patients with early-stage, hormone receptor-positive BC. Notably, initiation of treatment during endocrine therapy appeared to be associated with improved DFS (HR, 0.79; 95% CI, 0.66–0.95), breast cancer-free interval (HR, 0.76; 95% CI, 0.60–0.97) and distant recurrence-free interval (HR, 0.74; 95% CI, 0.56–0.97) [35]. A nationwide Danish prospective cohort study suggested that lipophilic statin use reduced the risk of recurrence at 10 years among 18,769 women with early-stage BC (HR, 0.73; 95% CI, 0.60–0.89). The protective effect was most pronounced in patients with hormone receptor-positive disease. The study included patients followed on the Danish Breast Cancer Cooperative

Parameters	Statin users	Non-statin users	<i>p</i> -value
	<i>n</i> = 423	<i>n</i> = 4381	1
Age			
Median (IOR), years	62 (57–68)	50 (43-58)	< 0.001
< 65 years, n (%)	256 (60.5)	3940 (89.9)	
> 65 years, n (%)	167 (39.5)	441 (10.1)	
Gender		()	
Female n (%)	418 (98.8)	4375 (99.9)	0.002
Male n (%)	5(1.2)	6(0,1)	0.002
Menopausal status	0 (112)	0 (011)	
Postmenopausal n (%)	380 (91.1)	2082 (47.6)	< 0.001
Premenopausal, n (%)	37 (8.9)	2288 (52.4)	0.0001
Missing n	1	5	
Men <i>n</i>	5	6	
BMI	5	0	
Median (IOR) kg/m^2	27 3 (24 1-31 5)	24 4 (21 9-28 0)	< 0.001
$< 30 \text{ kg/m}^2 n (\%)$	280 (66 2)	3647 (83.6)	0.001
$> 30 \text{ kg/m}^2 < 35 \text{ kg/m}^2 n (\%)$	93 (22 0)	475 (10.9)	
$> 35 \text{ kg/m}^2 n (\%)$	50 (11.8)	242(55)	
$\sum_{n=0}^{n} S(n) = S(n)$	50 (11.0)	17	
Type of surgery		17	
Breast conserving $n(\%)$	229 (54 1)	1965 (44.9)	< 0.001
Mastectomy n (%)	194 (45 9)	2413 (55.1)	< 0.001
Missing n	1)+ (+3.5)	3	
Histology		5	
Ductal n (%)	387 (91 5)	3945 (90.0)	0.33
Lobular $n(\%)$	12 (2.8)	112 (2.6)	0.55
Mixed DCIS I CIS n (%)	8 (1.9)	101(2.3)	
Other n (%)	16(3.8)	223(51)	
Nodal status	10 (3.8)	225 (5.1)	
n (%)	166 (39.2)	1633 (37 3)	0.32
1-3 n(%)	159 (37.6)	1648 (37.6)	0.52
$\sum_{n=0}^{\infty} n(\infty)$	(37.0)	1040(37.0)	
\geq 4, n (∞)	98 (23.2)	1100 (25.1)	
EP and PP $- n$ (%)	144 (34 0)	1488 (34 0)	0.97
ER and TR-, $n(n)$ ER and/or PR+ $n(n)$	144 (54.0) 279 (66 0)	2803 (66 0)	0.97
Tumor grade	217 (00.0)	2000 (00.0)	
1 n (%)	6 (1 5)	80 (2 1)	0.72
1, n(70)	134(33,3)	1305(33.1)	0.72
2, n(%)	154(55.5)	2735 (64.8)	
S, n(%)	202 (05.2)	2735 (04.8)	
	21	102	
0 1 0 m n (%)	105 (46 1)	1726 (30 5)	0.02
2 40 cm n (%)	193(40.1)	2255 (52.8)	0.02
2-4.9 cm, n (%)	201(47.5)	2555 (55.8)	
$\geq 5 \operatorname{cm}, n (10)$	27 (0.4)	29 4 (0.7) 6	
Randomization arm		U	
Dertuzumah = (%)	201 (47 5)	2100 (50.2)	0.20
Placebo n (%)	201 (47.3)	2177 (30.2)	0.29
Adjuvant chemotherany	222 (32.3)	2102 (49.0)	
Approximation \mathcal{A}	202(714)	2112 (70 6)	0.001
Antifiacyclific, $n(\%)$	502(71.4)	3442(78.0)	0.001
non-anumacycline, n(%)	121 (20.0)	939(21.4)	

Table 1 (continued)

Parameters	Statin users	Non-statin users	<i>p</i> -value
	<i>n</i> = 423	<i>n</i> = 4381	
Adjuvant radiotherapy			
No, <i>n</i> (%)	115 (27.2)	1207 (27.6)	0.87
Yes, <i>n</i> (%)	308 (72.8)	3174 (72.4)	
Adjuvant ET, $n = 3172$			
No, <i>n</i> (%)	50 (17.9)	455 (15.7)	0.35
Yes, <i>n</i> (%)	229 (82.1)	2438 (84.3)	
Diabetes			
No, <i>n</i> (%)	319 (75.4)	4210 (96.1)	< 0.001
Yes, <i>n</i> (%)	104 (24.6)	171 (3.9)	
Hypertension			
No, <i>n</i> (%)	152 (35.9)	3575 (81.6)	< 0.001
Yes, <i>n</i> (%)	271 (64.1)	806 (18.4)	
Coronary heart disease			
No, <i>n</i> (%)	406 (96.0)	4356 (99.4)	< 0.001
Yes, <i>n</i> (%)	17 (4.0)	25 (0.6)	
Hyperlipidemia			
No, <i>n</i> (%)	72 (17.0)	4230 (96.6)	< 0.001
Yes, <i>n</i> (%)	351 (83.0)	151 (3.4)	
Any of the above 4 comorbidities			
No, <i>n</i> (%)	16 (3.8)	3400 (77.6)	< 0.001
Yes, <i>n</i> (%)	407 (96.2)	981 (22.4)	

BMI body mass index, *DCIS* ductal carcinoma in situ, *ER* estrogen receptor, *ET* endocrine therapy, in ER+ and/or PR+ disease, *IQR* interquartile range, *LCIS* lobular carcinoma in situ; nodal status, number of positive lymph nodes, *PR* progesterone receptor

Group registry between 1996 and 2003 [32]. Other studies were unable to show a protective correlation between statin use and BC recurrence. The Life After Cancer Epidemiology Study including 1945 early-stage BC patients (diagnosed between 1997 and 2000) failed to show a statistically significant reduction in BC recurrences in patients receiving statins (rate ratio, 0.67; 95% CI, 0.39–1.13). Of note, lipophilic statins were mainly prescribed [36]. In line with these data, an analysis from the German MARIEplus study of more than 3000 patients with BC did not provide clear supportive evidence for an association between lipid-lowering drugs and BC outcome - both in terms of recurrence and BCspecific mortality [27]. A post-hoc analysis of the ABCSG-18 trial including patients with hormone receptor-positive BC suggested a worse DFS (HR, 1.35; 95% CI, 1.04–1.75) of patients receiving concomitant statins. Yet, after correction for possible confounders (age, smoking status, adjuvant chemotherapy) this effect subsided [39].

Regarding death from BC, a recent cancer registry analysis of 14,976 women diagnosed with BC between 2007 and 2016 in New Zealand found a protective association between statin use and BC-specific death (HR, 0.74; 95% CI, 0.63–0.86). In subgroup analysis, this association was restricted to women with hormone receptor-positive BC, postmenopausal women, women with advanced stage disease and prevalent statin users [20]. A cohort study of 13,378 females diagnosed with BC between 1995 and 2013 in Finland reported a protective association between postdiagnostic statin use and death from BC when the median total cholesterol decreased subsequently (HR, 0.49; 95% CI, 0.32-0.75). Yet, this risk difference was only statistically significant in hormone receptor-positive BC and not evident in triple-negative or HER2 + BC [22]. A nationwide cohort study in Scotland of 15,140 newly diagnosed BC patients from 2009 to 2012 within the Scottish Cancer registry did not find clear evidence of a protective association between post-diagnostic statin use and BC-specific mortality (HR, 0.95; 95% CI, 0.79–1.15) [31]. A meta-analysis in 2016, which included 10 studies with BC patients, suggested that statin use was associated with improvement in recurrencefree survival, overall survival and cancer-specific survival. At least the improvement in recurrence-free survival appeared to be confined to the use of lipophilic statins [17]. A recent meta-analysis which included 23 studies showed that statin use was associated with lower BC recurrence, all-cause mortality and disease-specific mortality [18]. It cannot be ruled out that the protective association between statin use and overall survival observed in some studies is due to a cardioprotective role of statins in patients with hormone receptor-positive disease taking aromatase inhibitors.





Fig. 1 Kaplan Meier curves for survival endpoints unadjusted for patient and disease characteristics. Time, in years, is measured from date of randomization; Twenty-five patients (5.9%) started statin treatment after randomization (median time from randomization to treatment start, 2.3 months; IQR, 2 days–6.6 months). Overall about 95% of statin users were under treatment at randomization (91%) or started within 3 months after randomization (4%). Two patients

It is not clear if the duration of statin exposure might play a role with regard to survival outcomes of BC patients. In the previously mentioned cohort study in New Zealand the risk for BC death generally decreased with increasing statin dosage over time. Other studies suggest that statins become more protective with increasing dose [9, 10, 13, 16, 22], while others have found no evidence of a dose dependency [11, 15, 19, 23, 31, 36]. Furthermore, two clinical trials that examined statin treatment in the neoadjuvant setting suggested a positive effect on reducing tumor proliferation even when taking statins only for a very short time [44, 45].

The majority of studies in the literature have not reported results of statin use in HER2 + BC or detailed information for this subgroup is missing. Preclinical models suggest that the mevalonate pathway, which can be targeted with statins, acts as an escape mechanism of survival and growth in HER2 + BC resistant to anti-HER2 therapies [40]. In line with the subgroup analysis in the BIG 1–98 trial, we

started statin treatment after 1 year from randomization and were considered non-statin users. Results landmarked from 12 months after study enrolment, and those based on a time-varying Cox model analysis were similar to those depicted in this analysis measured from date of randomization. *CI* confidence interval, *DRFI* distant relapse-free interval, *HR* hazard ratio, *IDFS* invasive disease-free survival, *No.* number, *OS* overall survival

found that statin users were more likely to be diagnosed with smaller sized tumors than non-statin users [35]. Numerically there were slightly more distant relapses and more IDFS events among statin users than among non-statin users (7.8% vs 7.1% and 12.8% vs 10.4%, respectively) despite the fact that statin users were diagnosed with smaller sized tumors. Yet, in multivariate analysis (adjusted for tumor size, nodal status and the existence of comorbidities among others) and despite the biological rationale, the current analysis showed no association of statin use on IDFS, DRFI, or OS in this large patient cohort of early HER2 + BC. Hormone receptor status had no impact on the results. Statin use overall was associated with a trend to worse OS in univariate analysis. The results were not statistically significant and may be subject to residual confounding. It should come as no surprise that patients who take statins under the assumption of a concomitant disease could have a higher risk of death during the course of a clinical trial follow-up. In a competing
 Table 2
 Multivariate analysis of

IDFS, DRFI, and OS

Parameter	Patients, n	Events, n	Hazard ratio (95% CI)	<i>p</i> -value
IDFS				
Statin use				
No	4348	452	1.00	
Yes	417	51	1.11 (0.80–1.52)	0.54
Age group				
< 65 years	4161	429	1.00	
≥ 65 years	604	74	1.30 (0.98-1.72)	0.07
Menopausal status				
Premenopausal	2311	244	1.00	
Postmenopausal	2454	259	0.95 (0.78-1.16)	0.62
Hormone receptor status				
ER and/or PR positive	3148	316	1.00	
ER and PR negative	1617	187	1.10 (0.92–1.32)	0.30
BMI				
$< 30 \text{ kg/m}^2$	3911	404	1.00	
$\geq 30 \text{ kg/m}^2 < 35 \text{ kg/m}^2$	563	66	1.09 (0.83–1.42)	0.53
$\geq 35 \text{ kg/m}^2$	291	33	0.94 (0.65–1.36)	0.75
Diabetes				
No	4493	472	1.00	
Yes	272	31	0.93 (0.63–1.37)	0.71
Hypertension				
No	3700	375	1.00	
Yes	1065	128	1.13(0.90-1.42)	0.30
Coronary heart disease	1000	120	(0)0 1112)	0.20
No	4724	495	1.00	
Yes	41	8	1.96 (0.96–3.99)	0.06
Nodal status	11	Ū	1.90 (0.90 5.99)	0.00
0 nodes	1785	94	1.00	
1-3 nodes	1795	176	1 91 (1 48-2 46)	< 0.001
> 4 nodes	1185	233	3.86(3.01-4.95)	< 0.001
Tumor size	1100	200	5.00 (5.01 1.55)	0.001
0-1.9 cm	1906	152	1.00	
> 2 cm < 5 cm	2541	282	1.00 1 20 (0.98-1.47)	0.08
$\geq 2 \text{ cm} < 3 \text{ cm}$	318	69	1.20(0.90-1.47) 1.87(1.39-2.51)	< 0.001
<u>Z 5 cm</u> Treatment arm	510	07	1.07 (1.5)-2.51)	< 0.001
Placebo	2383	282	1.00	
Portuzumah	2383	202	0.78 (0.65, 0.03)	0.005
DPFI	2362	221	0.78 (0.03-0.95)	0.005
Statin use				
No	1218	300	1.00	
No	4348	309	1.00	0.25
Aga group	417	52	1.21 (0.81–1.81)	0.55
Age group	4161	304	1.00	
< 0.5 years	4101	304	0.00 (0.68, 1.45)	0.08
≥ 05 years	004	57	0.99 (0.06–1.45)	0.98
Promonomousol	2211	170	1.00	
r remenopausai	2311	1/9	1.00	0.49
rosumenopausal	2434	102	0.92(0.72-1.17)	0.48
FD and/ DD iii	2140	017	1.00	
ER and/or PR positive	5148	217	1.00	A
ER and PR negative	1617	124	1.05 (0.84–1.32)	0.66

Table 2 (continued)

Parameter	Patients, n	Events, n	Hazard ratio (95% CI)	<i>p</i> -value
BMI				
$< 30 \text{ kg/m}^2$	3911	277	1.00	
$\geq 30 \text{ kg/m}^2 < 35 \text{ kg/m}^2$	563	43	1.06 (0.76–1.47)	0.74
\geq 35 kg/m ²	291	21	0.87 (0.55–1.38)	0.57
Diabetes				
No	4498	324	1.00	
Yes	272	17	0.82 (0.49-1.38)	0.46
Hypertension				
No	3700	265	1.00	
Yes	1065	76	1.01 (0.76–1.35)	0.94
Coronary heart disease				
No	4725	336	1.00	
Yes	41	5	1.85 (0.75-4.56)	0.18
Nodal status				
0 nodes	1785	38	1.00	
1–3 nodes	1795	107	2.75 (1.90-3.99)	< 0.001
\geq 4 nodes	1185	196	7.58 (5.31–10.82)	< 0.001
Tumor size				
0–1.9 cm	1906	87	1.00	
$\geq 2 \text{ cm} < 5 \text{ cm}$	2541	197	1.34 (1.04–1.73)	0.02
\geq 5 cm	318	57	2.19 (1.55-3.09)	< 0.001
Treatment arm				
Placebo	2383	192	1.00	
Pertuzumab	2382	149	0.78 (0.63-0.96)	0.02
OS				
Statin use				
No	4348	234	1.00	
Yes	417	34	1.16 (0.78–1.73)	0.45
Age group				
< 65 years	4161	214	1.00	
≥ 65 years	604	54	1.47 (1.05-2.06)	0.02
Menopausal status				
Premenopausal	2311	97	1.00	
Postmenopausal	2454	171	1.52 (1.15-2.01)	0.004
Hormone receptor status				
ER and/or PR positive	3148	147	1.00	
ER and PR negative	1617	121	1.46 (1.14–1.86)	0.002
BMI				
$< 30 \text{ kg/m}^2$	3911	213	1.00	
$\geq 30 \text{ kg/m}^2 < 35 \text{ kg/m}^2$	563	33	0.95 (0.65-1.38)	0.80
\geq 35 kg/m ²	291	22	1.20 (0.76–1.89)	0.44
Diabetes				
No	4493	248	1.00	
Yes	272	20	0.94 (0.58-1.52)	0.80
Hypertension				
No	3700	189	1.00	
Yes	1065	79	1.11 (0.82–1.51)	0.49
Coronary heart disease				
No	4724	263	1.00	
Yes	41	5	1.78 (0.72–4.37)	0.21
Nodal status				

Table 2 (continued)

Parameter	Patients, n	Events, n	Hazard ratio (95% CI)	<i>p</i> -value
0 nodes	1785	48	1.00	
1-3 nodes	1795	85	1.84 (1.29–2.63)	< 0.001
\geq 4 nodes	1185	135	4.10 (2.91–5.78)	< 0.001
Fumor size				
0–1.9 cm	1906	72	1.00	
$\geq 2 \text{ cm} < 5 \text{ cm}$	2541	152	1.37 (1.03–1.82)	0.03
\geq 5 cm	318	44	2.40 (1.62-3.55)	< 0.001
Freatment arm				
Placebo	2383	143	1.00	
Pertuzumab	2382	125	0.87 (0.69–1.11)	0.27

None of the two-way interaction terms with statins use reached statistical significance. Therefore, the multivariate analysis reports only the main effects. For the multivariate analysis, only patients for whom all variables were available (n = 4765) were included

BMI body mass index, *CI* confidence interval, *DRFI* distant relapse-free interval, *ER* estrogen receptor, *IDFS* invasive disease-free survival; nodal status, number of positive lymph nodes, *OS* overall survival; *PR* progesterone receptor

risk analysis with the event of interest being death due to BC, statin treatment was not associated with outcome. Of note, statin users were treated less frequently with anthracycline-containing regimens than non-statin users which might have influenced the results. In contrast to some observational studies, neither lipophilic nor hydrophilic statin use was associated with an improved outcome.

Study limitations

Some limitations exist in our study: (a) the exploratory nature of the analysis—the association between statin use and BC outcome was not a predefined hypothesis; (b) the vast majority of patients who received statins (91%) were receiving them at enrolment to APHINITY, although in 54% of cases the exact start date of statin co-medication was not available; (c) statin adherence was not systematically assessed and checked. Hence, we cannot exclude that some patients were non-adherent to treatment or might have received statins only for a short period of time; (d) the documentation of causes of death within APHINITY (especially considering competing events) might not have been optimal; e) lipid parameters were not collected either at baseline or during the course of the study, so it is not possible to draw any conclusions about a possible association with the outcome.

The strength of our analysis lies in the evaluation of a large, prospective phase 3 study with comprehensive information on patient and tumor characteristics and information on disease recurrence, type of recurrence, and deaths. To the best of our knowledge, our analysis is the largest focusing on statin co-medication in patients with early HER2 + BC.

In conclusion, in our analysis the use of statins within the APHINITY trial was not associated with improved outcomes in terms of IDFS, DRFI, and OS in patients with early HER2 + BC. Only a prospective, randomized study would be able to clarify whether the prognosis of patients with early breast cancer could be improved by statins. However, considering the high costs and complexity of running such a trial, it remains questionable whether this will ever happen. So far, apart from the current known indications for statin use, adding statins for early HER2-positive breast cancer is not recommended.

Table 3 Multivariate analysis of IDFS, DRFI, and OS—Sensitivity analyses. No significant interaction between statin use, obesity, treatment arm, hormone receptor status, and survival could be detected (all *p*-values > 0.05). In multivariate analysis, factors that were associated with worse OS were larger tumor size, nodal positivity, hormone receptor negativity, older age and postmenopausal status. Factors associated with worse IDFS and DRFI were larger tumor size, nodal positivity and placebo treatment (Table 2). In a competing risk analysis with the outcome of interest being death due to breast cancer, statin treatment was not associated with a better or worse outcome (HR, 1.29; 95% CI, 0.77–2.19; *p*-value = 0.34)

Parameter	Patients, n	Events, n	Hazard ratio (95% CI)	p-value
Landmark	at 12 months			
IDFS				
Statin u	se			
No	4160	399	1.00	
Yes	393	44	1.13 (0.80–1.59)	0.49
DRFI				
Statin u	se			
No	4160	276	1.00	
Yes	393	31	1.31 (0.86–1.97)	0.20
OS				
Statin u	se			
No	4160	198	1.00	
Yes	393	28	1.15 (0.74–1.78)	0.53
Start statin	as time-depe	endent covar	riate	
IDFS				
Statin u	se			
No	4348	452	1.00	
Yes	417	51	1.11 (0.81–1.53)	0.52
DRFI				
Statin u	se			
No	4348	309	1.00	
Yes	417	32	1.21 (0.81–1.81)	0.35
OS				
Statin u	se			
No	4348	234	1.00	
Yes	417	34	1.17 (0.79–1.73)	0.44

CI confidence interval, *DRFI* distant relapse-free interval, *IDFS* invasive disease-free survival, *OS* overall survival

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10549-025-07699-2.

Acknowledgements We thank all APHINITY participants for their contribution to our research work. We confirm that this is an original manuscript and has not been previously published or is submitted to another journal.

Author contributions Christian Maurer and Evandro de Azambuja had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Christian Maurer, Matteo Lambertini, Rachel Schiff, Carmine de Angelis, Martine Piccart and Evandro de Azambuja were responsible for the study conception and design. Christian Maurer, Elisa Agostinetto, Matteo Lambertini, Samuel Martel, Noam Ponde, Mariana Brandão, Francesca Poggio, Arlindo Ferreira, Richard Gelber and Evandro de Azambuja contributed to the methodology. Material preparation and data collection were performed by Christian Maurer, Lieveke Ameye, Richard Gelber, Susan Dent, Christoph Thomssen, Martine Piccart and Evandro de Azambuja. Formal analysis was performed by Lieveke Ameye. The first draft of the manuscript was written by Christian Maurer and Elisa Agostinetto and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The APHINITY trial was funded by F. Hoffmann–La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877).

Data availability Data are available upon reasonable request. Data and results are available at the Data Centre at Institut Jules Bordet in Brussels (Belgium) and can be made available upon approval of a research proposal.

Declarations

Competing interests There are no conflicts of interest related to the study design or its results. Christian Maurer declares travel grants from Mundipharma, Amgen, Servier Deutschland GmbH, Abbvie, and consulting fees from Abbvie, Celgene/BMS and Pfizer. He received honoraria for lectures from Daiichi Synkyo and Novartis. Elisa Agostinetto declares advisory board and/or honoraria from Eli Lilly, Sandoz, Astra-Zeneca, Abscint; she declares research grant to her Institution from Gilead, meeting/travel grants from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, and AstraZeneca (all outside the present work). Lieveke Ameye declares no conflict of interests. Matteo Lambertini declares advisory role for Roche, Lilly, Novartis, Astrazeneca, Pfizer, Seagen, Gilead, MSD and Exact Sciences and speaker honoraria from Roche, Lilly, Novartis, Astrazeneca, Pfizer, Sandoz, Libbs, Daiichi Sankyo, Knight, Ipsen and Takeda, travel grants from Gilead and Daiichi Sankyo, and research support (to the Institution) from Gilead outside the submitted work. Noam Ponde is an employee of IQVIA Biotech. Mariana Brandão declares advisory board fees and/or honoraria from Roche/GNE, Janssen, BMS, Amgen, Takeda, Pierre-Fabre, travel grants from Roche/GNE, Sanofi and Takeda and research grants to her institution from Roche/GNE, AstraZeneca, GSK/ Novartis and Servier. Francesca Poggio declares advisory board fees and/or honoraria from EliLilly, Novartis, AstraZeneca, Daichii Sankyo, and Seagen, meeting travel from Gilead, Pfizer, Pierre Fabre. Arlindo Ferreira declares honoraria and/or advisory board fees from Daiichi Sankyo, Gilead, Merck Sharp & Dohme, Novartis, Roche and travel grants from Roche. He is an employee of Resilience. Rachel Schiff declares research funding/grants to her institution (past and present) from AstraZeneca, GlaxoSmithKline, Puma, Biotechnology Inc, and Gilead Sciences, speaker honoraria and/or travel expenses from Binaytara Foundation and Dava Oncology, LP, and advisory board fees from Eli Lilly Daiichi Sankyo (Ad hoc), and Macrogenics. She declares royalties from UpToDate, is co-inventor in the Baylor College of Medicine's pending patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response), and has served as a member of the SABCS (Breast cancer symposium) Faculty/Planning Committees. Carmine De Angelis declares advisory role for Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Daichi Sankyo, Gilead, and GSK and speaker honoraria from Roche, Lilly, Novartis, Pfizer, Seagen, GSK, Gilead, and Daiichi Sankyo. He declares travel grants from Gilead and research support (to the Institution) from Novartis, GILEAD, and Daiichi-Sankyo outside the submitted work. He is co-inventor in the Patent application # PCT/ US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response). Richard D Gelber declares institutional funding from Roche, AstraZeneca, Merck. Susan Dent declares grant funding and honararia from Novartis. Christoph Thomssen declares advisory role and/or speaker honoraria from Amgen, AstraZeneca, Aurikamed GmbH, Daiichi Sankyo, Gilead, Hexal, Joerg Eickeler, Lilly, Medupdate GmbH, Medicultus Kassel GmbH, MSD, Novartis, Onkowissen TV, Pfizer, Roche, Roland Berger GmbH, Seagen, Streamedup GmbH. Martine Piccart is board member from Oncolytics and declares honoraria from AstraZeneca, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Roche-Genentech, Seattle Genetics, Seagen, NBE Therapeutics, Frame Therapeutics. She declares institutional research grants from AstraZeneca, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon, Gilead. Evandro de Azambuja declares honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs, Pierre Fabre, Lilly, Astra-Zeneca, MSD, Gilead Sciences; Travel grants from Roche/GNE and AstraZeneca; he declares research grant to his institution from Roche/GNE, AstraZeneca, and GSK/Novartis, Gilead Sciences; he is ESMO director of Membership 2023-2024 and BSMO President 2023-2026.

Ethical approval Here we present an exploratory analysis of the APHINITY trial. The institutional review board at each participating center approved the APHINITY trial protocol.

Consent to participate All patients in APHINITY provided written informed consent.

Consent to publish Not applicable as the manuscript does not contain any individual person's data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Giordano SH, Franzoi MAB, Temin S et al (2022) Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol 40:2612–2635. https://doi.org/10.1200/JCO.22.00519
- Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389:2415–2429. https://doi.org/10.1016/S0140-6736(16)32417-5
- Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101–126. https://doi.org/10.1038/s41573-022-00579-0
- Connor AE, Schmaltz CL, Jackson-Thompson J, Visvanathan K (2021) Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer. Cancer 127:2614–2622. https://doi.org/10.1002/cncr.33530

- Mullen PJ, Yu R, Longo J et al (2016) The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer 16:718–731. https://doi.org/10.1038/nrc.2016.76
- Baek AE, Yu Y-RA, He S et al (2017) The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun 8:864. https://doi.org/ 10.1038/s41467-017-00910-z
- Robinson E, Nandi M, Wilkinson LL et al (2013) Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol 129:417–424. https://doi.org/10.1016/j.ygyno.2013.02.003
- Shibata M-A, Ito Y, Morimoto J, Otsuki Y (2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25:1887–1898. https://doi. org/10.1093/carcin/bgh201
- Smith A, Murphy L, Zgaga L et al (2017) Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer. Br J Cancer 117:588–596. https://doi.org/10.1038/ bjc.2017.227
- Borgquist S, Broberg P, Tojjar J, Olsson H (2019) Statin use and breast cancer survival—a Swedish nationwide study. BMC Cancer 19:54. https://doi.org/10.1186/s12885-018-5263-z
- Murtola TJ, Visvanathan K, Artama M et al (2014) Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS ONE 9:e110231. https://doi.org/10.1371/journal.pone. 0110231
- Hosio M, Urpilainen E, Hautakoski A et al (2020) Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study. Acta Oncol 59:1110–1117. https://doi.org/10.1080/0284186X.2020.1769858
- Nowakowska MK, Lei X, Thompson MT et al (2021) Association of statin use with clinical outcomes in patients with triple-negative breast cancer. Cancer 127:4142–4150. https://doi.org/10.1002/ cncr.33797
- Haukka J, Niskanen L, Auvinen A (2017) Risk of cause-specific death in individuals with cancer-modifying role diabetes, statins and metformin. Int J Cancer 141:2437–2449. https://doi.org/10. 1002/ijc.31016
- Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792–1802. https://doi.org/10.1056/NEJMoa1201735
- Li YR, Ro V, Steel L et al (2019) Impact of long-term lipidlowering therapy on clinical outcomes in breast cancer. Breast Cancer Res Treat 176:669–677. https://doi.org/10.1007/ s10549-019-05267-z
- Manthravadi S, Shrestha A, Madhusudhana S (2016) Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer 139:1281–1288. https://doi.org/10.1002/ijc.30185
- Zhao G, Ji Y, Ye Q et al (2022) Effect of statins use on risk and prognosis of breast cancer: a meta-analysis. Anticancer Drugs 33:e507–e518. https://doi.org/10.1097/CAD.000000000001151
- Cardwell CR, Hicks BM, Hughes C, Murray LJ (2015) Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 26:68–78. https://doi.org/10.1097/ EDE.0000000000000189
- Scott OW, TinTin S, Harborg S et al (2023) Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat 199:195–206. https://doi. org/10.1007/s10549-022-06815-w
- Inasu M, Feldt M, Jernström H et al (2022) Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study. Breast 61:123–128. https://doi.org/10.1016/j.breast.2022.01.003
- 22. Murto MO, Simolin N, Arponen O et al (2023) Statin use, cholesterol level, and mortality among females with breast cancer.

JAMA Netw Open 6:e2343861. https://doi.org/10.1001/jaman etworkopen.2023.43861

- Smith A, Murphy L, Sharp L et al (2016) De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer. Br J Cancer 115:592–598. https:// doi.org/10.1038/bjc.2016.232
- Bjarnadottir O, Feldt M, Inasu M et al (2020) Statin use, HMGCR expression, and breast cancer survival—the Malmö Diet and Cancer Study. Sci Rep 10:558. https://doi.org/10.1038/ s41598-019-57323-9
- Brewer TM, Masuda H, Liu DD et al (2013) Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 109:318–324. https://doi.org/10.1038/bjc.2013.342
- Desai P, Lehman A, Chlebowski RT et al (2015) Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control 26:529–539. https://doi.org/10.1007/ s10552-015-0530-7
- 27. Nickels S, Vrieling A, Seibold P et al (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 8:e75088. https://doi.org/10.1371/journal.pone.0075088
- Botteri E, Munzone E, Rotmensz N et al (2013) Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 140:567–575. https://doi.org/ 10.1007/s10549-013-2654-3
- Sim Y, Lim C, Phyu N et al (2022) The impact of statin use and breast cancer recurrence—a retrospective study in Singapore. Front Oncol 12:835320. https://doi.org/10.3389/fonc.2022.835320
- Shaitelman SF, Stauder MC, Allen P et al (2017) Impact of statin use on outcomes in triple negative breast cancer. J Cancer 8:2026–2032. https://doi.org/10.7150/jca.18743
- Mc Menamin ÚC, Murray LJ, Hughes CM, Cardwell CR (2016) Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer 16:600. https://doi.org/10.1186/ s12885-016-2651-0
- Ahern TP, Pedersen L, Tarp M et al (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103:1461–1468. https://doi. org/10.1093/jnci/djr291
- Chae YK, Valsecchi ME, Kim J et al (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29:585–593. https://doi.org/10.3109/07357 907.2011.616252
- 34. Lacerda L, Reddy JP, Liu D et al (2014) Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med 3:849–856. https://doi.org/10.5966/sctm.2013-0204
- 35. Borgquist S, Giobbie-Hurder A, Ahern TP et al (2017) Cholesterol, cholesterol-lowering medication use, and breast cancer

outcome in the BIG 1–98 study. JCO. https://doi.org/10.1200/ JCO.2016.70.3116

- Kwan ML, Habel LA, Flick ED et al (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109:573–579. https://doi.org/10.1007/s10549-007-9683-8
- Boudreau DM, Yu O, Chubak J et al (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144:405–416. https://doi.org/10.1007/s10549-014-2870-5
- Harborg S, Heide-Jørgensen U, Ahern TP et al (2020) Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Res Treat 183:153–160. https://doi. org/10.1007/s10549-020-05749-5
- Minichsdorfer C, Fuereder T, Leutner M et al (2022) Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. ESMO Open 7:100426. https://doi.org/10.1016/j.esmoop.2022. 100426
- Sethunath V, Hu H, Angelis CD et al (2019) Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer. Mol Cancer Res 17:2318–2330. https://doi. org/10.1158/1541-7786.MCR-19-0756
- von Minckwitz G, Procter M, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1703643
- 42. Piccart M, Procter M, Fumagalli D et al (2021) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY Trial: 6 years' follow-up. J Clin Oncol. https://doi. org/10.1200/JCO.20.01204
- 43. Gelber RD, Wang XV, Cole BF et al (2022) Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast CANCER: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4–11) trial. Eur J Cancer 166:219–228. https://doi.org/10.1016/j. ejca.2022.01.031
- 44. Garwood ER, Kumar AS, Baehner FL et al (2010) Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 119:137–144. https:// doi.org/10.1007/s10549-009-0507-x
- Bjarnadottir O, Romero Q, Bendahl P-O et al (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138:499–508. https:// doi.org/10.1007/s10549-013-2473-6

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Christian Maurer^{1,2} · Elisa Agostinetto³ · Lieveke Ameye³ · Matteo Lambertini^{4,5} · Samuel Martel^{6,7} · Noam Ponde⁸ · Mariana Brandão³ · Francesca Poggio⁵ · Arlindo Ferreira⁹ · Rachel Schiff¹⁰ · Carmine De Angelis¹¹ · Richard D. Gelber¹² · Susan Dent¹³ · Christoph Thomssen¹⁴ · Martine Piccart³ · Evandro de Azambuja³

Christian Maurer Christian.Maurer@med.uni-heidelberg.de

¹ National Center for Tumor Diseases (NCT) Heidelberg, University Hospital and German Cancer Research Center Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany

² Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

- ³ Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Rue Meylemeersch 90, 1070 Brussels, Belgium
- ⁴ Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy
- ⁵ Department of Medical Oncology, U.O. Clinical Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- ⁶ Specialised Medicine Department, CISSS Montérégie-Centre/Hôpital Charles-Le Moyne, Greenfield Park, Québec, Canada
- ⁷ Université of Sherbrooke, Sherbrooke, Québec, Canada
- ⁸ Clinical Development Department, Daiichi Sankyo, Morristown, NJ, USA

- ⁹ Católica Medical School, Universidade Católica Portuguesa, Lisbon, Portugal
- ¹⁰ Lester and Sue Smith Breast Center, Departments of Medicine and of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
- ¹¹ Medical Oncology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
- ¹² Harvard Medical School, Harvard TH Chan School of Public Health, Dana-Farber Cancer Institute, Frontier Science Foundation, Boston, MA, USA
- ¹³ Wilmot Cancer Institute, Department of Medicine, University of Rochester, Rochester, NY, USA
- ¹⁴ Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany